BRI2-derived beta amyloid inhibitor (RemeGenix)

N/A

Report date: 2025/01/26 19:11:04

Base Information

Drug NameBRI2-derived beta amyloid inhibitor (RemeGenix)
Drug Alias NameMoBA (RemeGenix)BRI2-derived beta amyloid inhibitor (Cortica Neurosciences)RGX-100
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRemeGenix Inc
China Registration ClassN/A

Develop Information

Active CompaniesRemeGenix Inc
Inactive CompaniesCortica Neurosciences Inc
Active IndicationsAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A